06:47 AM EDT, 07/29/2024 (MT Newswires) -- Integra LifeSciences Holdings ( IART ) reported Q2 adjusted earnings Monday of $0.63 per diluted share, down from $0.71 a year earlier.

Analysts polled by Capital IQ expected $0.62.

Revenue for the quarter ended June 30 was $418.2 million, up from $381.3 million a year earlier.

Analysts polled by Capital IQ expected $413.1 million.

The company now expects full-year 2024 adjusted EPS from $2.41 to $2.57, down from the previous outlook of $3.01 and $3.11. Analysts surveyed by Capital IQ are expecting $3.04.

Revenue for the full year is expected to be from $1.61 billion to $1.63 billion, also lower than the prior guidance of $1.67 billion to $1.69 billion. Analysts surveyed by Capital IQ are expecting $1.68 billion.

For Q3, Integra expects adjusted EPS of $0.36 to $0.44 on revenue of $372 million to $382 million. Analysts polled by Capital IQ expect $0.85 on $434.4 million.